PMC:7463108 / 106191-106492 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T91","span":{"begin":12,"end":30},"obj":"Chemical"},{"id":"T93","span":{"begin":21,"end":30},"obj":"Chemical"},{"id":"T84290","span":{"begin":44,"end":54},"obj":"Chemical"},{"id":"T94858","span":{"begin":55,"end":64},"obj":"Chemical"},{"id":"T64009","span":{"begin":75,"end":78},"obj":"Chemical"},{"id":"T31065","span":{"begin":149,"end":162},"obj":"Chemical"}],"attributes":[{"id":"A67777","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A2159","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A27095","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A3788","pred":"chebi_id","subj":"T84290","obj":"http://purl.obolibrary.org/obo/CHEBI_37924"},{"id":"A92040","pred":"chebi_id","subj":"T94858","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A36824","pred":"chebi_id","subj":"T64009","obj":"http://purl.obolibrary.org/obo/CHEBI_38559"},{"id":"A93307","pred":"chebi_id","subj":"T31065","obj":"http://purl.obolibrary.org/obo/CHEBI_3216"}],"text":"The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3597","span":{"begin":75,"end":82},"obj":"Gene"},{"id":"3598","span":{"begin":87,"end":94},"obj":"Gene"},{"id":"3604","span":{"begin":44,"end":54},"obj":"Chemical"},{"id":"3605","span":{"begin":55,"end":64},"obj":"Chemical"},{"id":"3606","span":{"begin":149,"end":162},"obj":"Chemical"},{"id":"3607","span":{"begin":167,"end":183},"obj":"Chemical"}],"attributes":[{"id":"A3597","pred":"tao:has_database_id","subj":"3597","obj":"Gene:1576"},{"id":"A3598","pred":"tao:has_database_id","subj":"3598","obj":"Gene:54658"},{"id":"A3604","pred":"tao:has_database_id","subj":"3604","obj":"MESH:D000069446"},{"id":"A3605","pred":"tao:has_database_id","subj":"3605","obj":"MESH:D019438"},{"id":"A3606","pred":"tao:has_database_id","subj":"3606","obj":"MESH:D002047"},{"id":"A3607","pred":"tao:has_database_id","subj":"3607","obj":"MESH:C043585"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T24","span":{"begin":271,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0050890"}],"text":"The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1335","span":{"begin":0,"end":301},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al."}